Related Experiment Video

Updated: Sep 24, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

885

Procoagulant Microvesicles in COVID-19 Patients: Possible Modulators of Inflammation and Prothrombotic Tendency

Hassan A Hamali1, Muhammad Saboor1,2, Gasim Dobie1

  • 1Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Jazan University, Gizan, Saudi Arabia.

Infection and Drug Resistance
|May 6, 2022
PubMed

Insights

Patients with COVID-19 show increased levels of procoagulant microvesicles (MVs) and tissue factor-bearing microvesicles (TF-bearing MVs). These MVs may serve as early indicators of disease severity and procoagulant activity in COVID-19 patients.

Area of Science:

  • * Hematology
  • * Immunology
  • * Virology

Background:

  • * Coronavirus disease 2019 (COVID-19) is associated with hypercoagulability and a thrombotic tendency.
  • * This tendency is multifactorial, primarily driven by inflammation and endothelial dysfunction.
  • * Elevated procoagulant microvesicles (MVs) and tissue factor-bearing microvesicles (TF-bearing MVs) are linked to thrombotic conditions.

Purpose of the Study:

  • * To quantify procoagulant MVs and TF-bearing MVs in COVID-19 patients versus healthy controls.
  • * To investigate correlations between MV levels and platelet counts, D-dimer, and inflammatory markers.

Main Methods:

  • * Enzyme-linked immunosorbent assay (ELISA) was used to measure MV levels.
  • * Plasma samples from 40 ICU-admitted COVID-19 patients and 37 healthy controls were analyzed.

Main Results:

  • * COVID-19 patients exhibited significantly higher levels of procoagulant MVs and TF-bearing MVs compared to controls (P<0.001).
  • * Procoagulant MVs showed significant positive correlations with TF-bearing MVs, D-dimer levels, and platelet counts.
  • * No significant correlations were found between MV levels and calculated inflammatory markers (neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, platelet/neutrophil ratio).

Conclusions:

  • * Elevated procoagulant MVs and TF-bearing MVs in COVID-19 patients suggest their potential as early predictive markers for disease severity.
  • * These microvesicles represent a novel circulatory biomarker for assessing COVID-19's procoagulant activity and overall severity.
Abstract

Keywords:
COVID-19D-dimerNLRPLRPNRmicrovesiclesprocoagulanttissue factor

More Related Videos

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

736
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.2K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
946
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
659
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.5K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
49
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
411